Previous 10 | Next 10 |
The small cap biotech space offers a powerful dimension for active investors because it is comprised of stocks with little or no consistent correlation with the broad market, creating diversification without sacrificing explosive upside potential. But the group is best handled in baskets. In ...
NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the Eur...
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy market. As per the article published in Cancer Connect 202...
Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases Results will be featured in a late-breaking podium presentation at The Liver Meeting ® NEW YORK, Nov....
Bloomberg reports this week that the VIX (the CBOE Volatility Index) is rallying with the S&P 500 in a rare way over the past few weeks. And recent analysis from Susquehanna suggests that this is not because people are bidding up put option contract prices out of valuation jitters but bid...
Image source: The Motley Fool. Intercept Pharmaceuticals, inc (NASDAQ: ICPT) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Intercept Pharmaceuticals, inc (ICPT) Q3 2021 Earnings Call T...
Start Time: 08:30 End Time: 09:31 Intercept Pharmaceuticals, Inc. (ICPT) Q3 2021 Earnings Conference Call November 03, 2021, 08:30 AM ET Company Participants Jerry Durso - President and CEO Linda Richardson - Chief Commercial Officer Michelle Berrey - President of Research and Development and...
Shares of Intercept Pharmaceuticals (ICPT +15.8%) are up in morning trading after the company beat Q3 2021 earnings expectations and raised its projected 2021 revenue for Ocaliva. Ocaliva sales reached $92.8M in the quarter, a 17% increase from the prior-year period. The company saw a signifi...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Intercept Pharma (NASDAQ:ICPT): Q3 GAAP EPS of -$0.11 beats by $0.98. Revenue of $92.87M (+16.8% Y/Y) beats by $9.83M. Press Release Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows Non-GAAP adjusted operating expense gu...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...